Pfizer eyes obesity drug market as it seals $4.9bn deal for Metsera Pharma giant Pfizer is betting on obesity treatments as it looks for new markets following the success of its COVID-19 vaccine. Euronews · Sep 22, 2025
Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal Pfizer Inc. (NYSE:PFE) on Monday agreed to acquire Metsera, Inc. (NASDAQ:MTSR) to accelerate the next generation of medicines for obesity and cardiometabolic diseases. Benzinga · Sep 22, 2025
Pfizer amps up push into obesity treatments with $4.9B deal for Metsera Pfizer is doubling down on obesity treatments by spending $4.9 billion on the development-stage drugmaker Metsera The Independent UK · Sep 22, 2025
Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market Pfizer Inc. (NYSE:PFE) stock climbed 1.54% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ:MTSR), a developer of anti-obesity drugs. Benzinga · Sep 22, 2025